Last reviewed · How we verify
NCT06461182: PentixaFor
Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma
Phase 2 trial testing Ga-68-CXCR4 in Indolent B-Cell Non-Hodgkin Lymphoma in 15 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Koo Foundation Sun Yat-Sen Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 15 |
| Start date | 29 April 2024 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Ga-68-CXCR4 — full drug profile →
Conditions studied
- Indolent B-Cell Non-Hodgkin Lymphoma — all drugs for Indolent B-Cell Non-Hodgkin Lymphoma →
Sponsor
Koo Foundation Sun Yat-Sen Cancer Center
Who can join
Adults 20 to 100, any sex, with Indolent B-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Performance of Ga-68-CXCR4 PET/CT in indolent B cell lymphoma
Time frame: up to 24 months
Detection rate = number of positive scan / total number of scan Sensitivity = number of true positive scan / total number of proven recurrent patient Specificity = number of true negative scan / total number of proven free of disease patient Accuracy = number of (true positive scan + true negative scan) / total number of scan Positive predictive value = number of true positive scan / number of pos
Sponsor's own description
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent Updates of PET in Lymphoma: FDG and Beyond.
Kim SY, Chung HW, So Y, Lee MH, et al · · 2024 · cited 2× · PMID 39595051 · DOI 10.3390/biomedicines12112485 -
Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?
Hartrampf PE, Werner RA, Higuchi T, Schottelius M, et al · · 2026 · PMID 41819832 · DOI 10.2967/jnumed.125.271153
Verify or expand the search:
- PubMed search for NCT06461182
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Indolent B-Cell Non-Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06386315 — Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma · Phase 2 · recruiting
- NCT05025800 — ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · Phase 1, PHASE2 · active not recruiting
- NCT03571568 — A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL · Phase 1, PHASE2 · recruiting
Other Koo Foundation Sun Yat-Sen Cancer Center trials
Trials by the same sponsor.
- NCT06769828 — Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA · NA · recruiting
- NCT06531135 — A RCT of Psychosocial Interventions Facilitating Positive Psychological Adaptation in Breast Cancer · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06461182 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Koo Foundation Sun Yat-Sen Cancer Center
- Last refreshed: 11 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06461182.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing